copper-catalyzed coupling of oximeacetates with isothiocyanates. Various 4-substituted and 4,5-disubstituted 2-aminothiazoles were formed smoothly under mild reaction conditions. This process involved copper-catalyzed N–O bond cleavage, activation of vinyl sp2 C–H bonds, and C–S/C–N bond formations. It is noteworthy that the oximeacetates were used not only as a substrate but also as a single oxidant
Thiocyanation and 2-Amino-1,3-thiazole Formation in Water Using Recoverable and Reusable Glycosylated Resorcin[4]arene Cavitands
作者:Ali A. Husain、Kirpal S. Bisht
DOI:10.1021/acs.joc.0c01150
日期:2020.8.7
resorcin[4]arene cavitand glycoconjugates (RCGs) have been applied as efficient recoverable and reusable inverse phase transfer catalysts for eco- and environmentally friendly thiocyanation and 2-amino-1,3-thiazole formation reactions in water. The results show that RCGs (1 mol %) were capable of hosting and catalyzing various water-insoluble bromo/thiocyanato substrates in water without the use of any co-organic
Highly Efficient Heterogeneous Copper-Catalysed Coupling of Oxime Acetates with Isothiocyanates Leading to 2-Aminothiazoles
作者:Yuxin Tuo、Fang Yao、Yang Liao、Mingzhong Cai
DOI:10.3184/174751917x14894997017739
日期:2017.4
The heterogeneous coupling reaction of oxime acetates with isothiocyanates was achieved at 110 °C in toluene in air in the presence of a bidentate nitrogen-functionalised MCM-41-immobilised copper(I) complex (MCM-41-2N-CuI) with Cs2CO3 as base to afford a variety of 2-aminothiazoles in good yields. The MCM-41-2N-CuI catalyst can be easily recovered by a simplefiltration and reused at least eight times
COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF
申请人:Thiele Dennis J.
公开号:US20110112073A1
公开(公告)日:2011-05-12
The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.